Compare KREF & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KREF | TECX |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.4M | 371.0M |
| IPO Year | 2015 | 2018 |
| Metric | KREF | TECX |
|---|---|---|
| Price | $5.40 | $20.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $7.00 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 924.6K | 159.4K |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.46% | N/A |
| EPS Growth | N/A | ★ 40.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $349.17 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.94 | $16.77 |
| 52 Week High | $9.11 | $39.53 |
| Indicator | KREF | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 43.37 |
| Support Level | $5.09 | $18.54 |
| Resistance Level | $6.01 | $23.03 |
| Average True Range (ATR) | 0.34 | 1.25 |
| MACD | 0.02 | 0.36 |
| Stochastic Oscillator | 42.60 | 46.07 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.